Ascent Pharmaceuticals, USA
Dr. Meghana Vidiyala from Ascent Pharmaceuticals, USA
The objective of this work is to develop and characterize Nano-emulsion based transdermal system (NTS) having Lidocaine in Nano-emulsion form. This second generation Nano-emulsion based transdermal drug delivery system has several advantages over traditional gel and transdermal systems (TS). NTS are therapeutically more effective compared to gel and conventional transdermal patches. Nano-emulsion components including surfactants and co-surfactants enhance skin permeability thereby increasing therapeutic efficacy and bioavailability of the drug molecule. Moreover, the release profile can be modulated by altering the ratio between surfactant, co-surfactant, and solvents.